*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Atlanta, GA | Posted: June 4, 2014
Summary Sentence:
Following news the Food and Drug Administration has approved CardioMEMS's wireless heart monitoring device, St. Jude Medical Inc. said on Wednesday, May 28th, that it plans complete its acqusition of shares of the biotech company CardioMEMS.
Full Summary:
No summary paragraph submitted.
CardioMEMS DeviceFollowing news the Food and Drug Administration has approved CardioMEMS's wireless heart monitoring device, St. Jude Medical Inc. said on Wednesday, May 28th, that it plans complete its acqusition of shares of the biotech company CardioMEMS it does not already own for $375 million.
The FDA approved CardioMEMS implantable device is intended for the treatment of patients with chronic pulmonary disease. The miniature device records and transmits pulmonary artery pressure for the remote monitoring of patients by physicians.
CardioMEMS was founded in 2001 by cardiologist Jay Yadav and Mark Allen, a Georgia Tech nanotechnology professor. Yadav predicts a growth in Atlanta hiring due to the acquisition as the company's headquarters is expected to stay in the area.
Read the full story at the AJC here.
